Matinas BioPharma MTNB Q1 2026 Annual earnings
Reported May 8, 2026 · After market close
EPS-$0.30Beat by $1.02
Revenue estimate$25.0K
EPS estimate-$1.32
Next report
Aug 13, 2026 (In 2 weeks)Revenue estimate$25.0K
EPS estimate-$1.50
Versus estimates
Revenue
Diluted EPS
Q1 2026-$0.30Beat by $1.02
Q4 2025-$0.24Beat by $1.08Q3 2025-$0.40Q2 2025-$1.03Q1 2025-$1.68Miss by $0.90Q4 2024-$1.50Miss by $0.72Ask the moment Matinas BioPharma reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Matinas BioPharma report Q1 2026 earnings?
- Matinas BioPharma (MTNB) reported Q1 2026 earnings on May 8, 2026 after market close.
- What were Matinas BioPharma's Q1 2026 revenue and EPS?
- Matinas BioPharma reported eps of $-0.30 for Q1 2026.
- Did Matinas BioPharma beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-1.32 by $1.02.
- How did Matinas BioPharma's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 82.1% from $-1.68.
- Where can I find Matinas BioPharma's Q1 2026 SEC filings?
- You can read the 10-K periodic report (0001493152-26-014132) directly on SEC EDGAR. The filing index links above go to sec.gov.